Genentech and Tanvex reach agreement-in-principle in trastuzumab case

Genentech and Tanvex BioPharma filed a joint notice of settlement in the District Court of the Southern District of California, notifying the court that they have reached an agreement-in-principle to resolve all pending claims in relation to their dispute over Tanvex’s BLA submission for a biosimilar trastuzumab.  The parties stated that they expect the final executed Joint Stipulation of Dismissal of all claims will be filed within 30 days.